A once-weekly oral regimen can keep HIV suppressed as well as daily pills, according to study results presented today at the Conference on Retroviruses and Opportunistic Infections (CROI 2024).

Two long-acting antiretrovirals, lenacapavir (Sunlenca) and cabotegravir (Vocabria), may pair well with broadly neutralising antibodies for HIV treatment, according to two presentations yesterday at the Conference on Retroviruses and Opportunistic Infections (CROI 2024).

The number of new HIV diagnoses has continued to drop steeply between 2012 and 2021 in US states with the highest coverage of PrEP (regular medication to prevent HIV), according to research presented by Dr Patrick Sullivan at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) yesterday.

Two antiretrovirals with the potential for once-weekly oral dosing were unveiled at CROI 2024 in Denver on Monday. The new agents have undergone phase 1 studies, which establish appropriate dosing and weed out drugs which have serious side effects. Before becoming available for prescription, drugs go through two further phases of testing to establish their efficacy, dosing and safety. During these stages of development many products fall by the wayside either because unexpected problems arise or the commercial priorities of the pharmaceutical company change.

This week’s Conference on Retroviruses and Opportunistic Infections (CROI 2024) heard the latest data from research involving giving people a cocktail of three broadly neutralising antibodies (bnAbs), which aidsmap last reported on two years ago.

En vísperas del Día Internacional de la Mujer, que se celebra el 8 de marzo, ONUSIDA hace un llamamiento a la protección de los derechos de las mujeres para proteger su salud.

Analysis of tissue samples from six people with HIV who passed away due to terminal illness revealed varying concentrations of dolutegravir in different body sites and organs. Unsurprisingly, drug concentrations in the brain and the spinal cord were lower than in other body sites, but concentrations across different parts of the brain were evenly distributed. In contrast, the intestines and the spleen – where a large portion of the immune system resides – were found to have high drug concentrations.

Services providing post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) need to build stronger connections between these two ways of preventing HIV infection, so as to help people who’ve used one method to access the other, according to experts at the Conference on Retroviruses and Opportunistic Infections (CROI 2024). [SHORTCUT id=”33793”]

Taking the antibiotic doxycycline after sex appears to have lowered the incidence of sexually transmitted infections (STIs) in San Francisco, according to researchers who presented some of the earliest real-world data yesterday at the Conference on Retroviruses and Opportunistic Infections (CROI 2024). [SHORTCUT id="35118"]

A year ago, the DoxyVAC study’s interim results raised hopes that by combining post-exposure prophylaxis using the antibiotic doxycycline (‘doxyPEP’) with a candidate vaccine against gonorrhoea, cases of all three of the most important bacterial sexually transmitted infections could be substantially reduced in gay and bisexual men.

Injectable treatment with cabotegravir and rilpivirine proved just as effective in maintaining viral suppression as standard oral antiretroviral treatment in a large trial in Africa, despite less intensive viral load monitoring than previous studies, Professor Nicholas Paton of the London School of Hygiene and Tropical Medicine reported at the Conference on Retroviruses and Opportunistic Infections in Denver on Monday.

Young people living with HIV in South Africa recently identified their priority research questions as part of an approach which moves away from biomedical research being led by researchers to communities taking the lead. Their priorities were published in PLOS Global Public Health.

As well as lowering levels of harmful cholesterol, statin treatment in people with HIV may cut the risk of heart disease by reducing the size and instability of fat deposits in arteries, according to a sub-study of the REPRIEVE trial published in the journal JAMA Cardiology.

A recent study explored the preferences of adolescent and young adults in Kenya regarding when and how disclosure should happen, along with their satisfaction with the process.

Women with HIV who gained weight during pregnancy after starting dolutegravir-based treatment were less likely to experience birth outcomes such as premature birth, stillbirth or an infant that was small for gestational age, analysis of a large clinical trial has shown. Weight gained during pregnancy was more likely to be maintained in the year after giving birth by women taking dolutegravir than those taking efavirenz, especially if dolutegravir was taken with tenofovir alafenamide (TAF).

El Día de la Cero Discriminación fue establecido por ONUSIDA hace diez años para promover la igualdad y la equidad para todas las personas, independientemente del género, la edad, la sexualidad, el origen étnico o el estado serológico respecto al VIH. Sin embargo, los avances están en peligro.

Antiretroviral treatment using monthly cabotegravir and rilpivirine injections is more effective than daily pills for people who have had difficulty achieving good adherence and  maintaining viral suppression, according to an announcement this week from ViiV Healthcare.

In April, almost two years ago, I started experiencing stabbing pains. They were intense but intermittent and I was very busy at the time so I tried to ignore them. I had a live broadcast that I was scheduled to do for aidsmap and I didn’t want to miss that.

Monitoring of CD4/CD8 ratios should not be abandoned as HIV treatment programmes switch to streamlined monitoring, researchers from the University of Wisconsin argue in the journal AIDS. Highlighting recently published research that shows the value of CD4/CD8 ratios for predicting who is at greater risk of cancer and weak vaccine responses, they say that the CD4/CD8 ratio remains an important biomarker for guiding individualised care in people with HIV.

Taking an ACE inhibitor that crosses the blood-brain barrier reduced the risk of being diagnosed with dementia and delayed the time to a diagnosis of dementia in people with HIV receiving care in Veterans Affairs clinics in the United States, researchers report. The study compared people who took an ACE inhibitor that crosses the blood-brain barrier and those who took no medication or another type of medication to treat high blood pressure. The findings have been published as a pre-print but await full peer review.